MWNA
TMDX icon

Marshall Wace North America’s Transmedics TMDX Stock Holding History

Marshall Wace North America’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-40,577
Closed -$1.18M – 1555
2019
Q2 		$1.18M Buy
+40,577
New +$1.11M 0.01% 704

Other funds holding TMDX

ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.23B AUM 13.7% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace North America's TMDX Position: Q3 2019 in Review

Marshall Wace North America sold out of Transmedics (TMDX) in Q3 2019, closing a stake of 40,577 shares — an estimated $1.18M sold.

Marshall Wace North America first reported a position in TMDX in Q2 2019 and held it in 1 quarter. The position peaked at $1.18M in Q2 2019. 50 funds tracked by Wall St. Rank hold TMDX as of Q3 2019.

  • Marshall Wace North America reported no remaining Transmedics position as of Q3 2019 after selling out during the quarter.
  • Marshall Wace North America sold 40,577 Transmedics shares in Q3 2019, an estimated $1.18M.
  • Marshall Wace North America first reported a position in Transmedics in Q2 2019 and held it in 1 quarter.
  • Marshall Wace North America's Transmedics position peaked at $1.18M in Q2 2019.
  • 50 funds tracked by Wall St. Rank held Transmedics as of Q3 2019.

Based on Marshall Wace North America's 13F filing for Q3 2019, filed 14 Nov 2019.